CDK4/6 inhibitors enhance the expression of genes that control the processing and presentation of antigens on the surface of cancer cells, inhibit the Rb-EF2 pathway (Goel et al. 2022), reduce the activity of DNA methyltransferases, inhibit the proliferation of regulatory T cells, prime cytotoxic T lymphocytes for eliminating tumor cells and heighten their antitumor functions (Morrison et al. 2024). Here, CDK4 is linked to neoplasm.